PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
Source: SeekingAlpha
2026-01-28 12:16:27 ET
I have been a long-time bull for Pacific Biosciences ( PACB ). The company is known for its long-read sequencing systems. The company sells these devices to labs and earns recurring revenue as they buy consumables (SMRT Cells, reagents, and kits). We can broadly split the revenue into instruments (one-time CapEx purchases of devices like Revio and Vega) and service & utilization revenue (support and consumables). Revio is the flagship workhorse, while Vega is a lower-throughput, lower-price benchtop system aimed at smaller organizations....
Read the full article on Seeking Alpha
For further details see:
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
Pacific Biosciences of California Inc.
NASDAQ: PACB
PACB Trading
5.2% G/L:
$1.415 Last:
2,496,776 Volume:
$1.43 Open:
PACB Latest News
March 05, 2026 08:30:00 am
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
February 24, 2026 09:05:00 am
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
February 18, 2026 04:05:00 pm
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
PACB Stock Data
$549,471,524
294,359,745
0.64%
78
N/A
Biotechnology & Life Sciences
Healthcare
US
Menlo Park
